Modified Delphi Study on Oral Mucositis/Stomatitis Prevention and Management in Patients Receiving Datopotamab Deruxtecan
European Journal of Cancer Care · 2026-01 · 2026 (1)
DOI: 10.1155/ecc/6518713 ↗Kurz gefasst
Delphi-Studie in der Zeitschrift European Journal of Cancer Care, online erschienen am 28.03.2026. Verfasst von Paolo Bossi und 17 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, Daiichi Sankyo Company.
Abstract (Originalsprache)
Background
Oral mucositis/stomatitis is a common adverse event during cancer treatment that can disrupt oral functioning and adherence to treatment. Datopotamab deruxtecan (Dato‐DXd), a TROP2‐directed antibody‐drug conjugate, has shown promise in treating solid tumors. It has been associated with oral mucositis/stomatitis in clinical trials for breast and lung cancer (TROPION program). Currently, there is a lack of formalized guidelines for managing Dato‐DXd‐associated oral mucositis/stomatitis. The present study employed a modified Delphi approach to establish expert consensus on preventing, diagnosing, monitoring, and treating oral mucositis/stomatitis secondary to Dato‐DXd and to improve patient care and clinical outcomes. Materials and Methods A four‐stage modified Delphi study engaging 15 oncology experts from Europe and Canada was used to establish consensus on managing Dato‐DXd‐induced oral mucositis/stomatitis in lung and breast cancer patients. Experts were selected based on their roles as investigators in Dato‐DXd clinical trials, including but not limited to TROPION‐PanTumor01, TROPION‐Lung01, TROPION‐Lung05, and TROPION‐Breast01, and their experience managing cancer treatment–associated oral mucositis/stomatitis. The Delphi process included an initial meeting, two anonymized surveys, an in‐person consensus meeting, and virtual one‐to‐one sessions for absentees.
Results
Expert consensus was reached on recommendations for managing Dato‐DXd‐associated oral mucositis/stomatitis, and experts highlighted the importance of establishing guidance to improve patient quality of life and clinical outcomes. Key recommendations included prophylactic dexamethasone mouthwash, patient education, and behavioral changes. Early detection through self‐checks and monitoring was emphasized, and recommended treatment strategies were tailored to oral mucositis/stomatitis severity. Treatment recommendations included dose modifications and discontinuation for severe cases.
Conclusions
This study offers expert guidance on managing Dato‐DXd‐associated oral mucositis/stomatitis, filling a crucial gap in patient care. Ongoing efforts to generate Dato‐DXd‐specific data will facilitate the creation of standardized, evidence‐based protocols to improve patient safety and treatment outcomes.
Förderung
- AstraZeneca
- Daiichi Sankyo Company
Zitieren
APA
Bossi, P., Atmaca, A., Bachelot, T., Bartsch, R., Bianchini, G., Chu, Q., Cornelissen, R., Felip, E., Girard, N., Passiglia, F., Pernas, S., Phillips, M., Planchard, D., Zamagni, C., Clark, J., Matthews, C., Goerke, L., & Pistilli, B. (2026). Modified Delphi Study on Oral Mucositis/Stomatitis Prevention and Management in Patients Receiving Datopotamab Deruxtecan. European Journal of Cancer Care, 2026(1). https://doi.org/10.1155/ecc/6518713
Vancouver
Bossi P, Atmaca A, Bachelot T, Bartsch R, Bianchini G, Chu Q, et al. Modified Delphi Study on Oral Mucositis/Stomatitis Prevention and Management in Patients Receiving Datopotamab Deruxtecan. European Journal of Cancer Care. 2026;2026(1). doi:10.1155/ecc/6518713
BibTeX
@article{Bossi2026,
author = {Bossi, Paolo and Atmaca, Akin and Bachelot, Thomas and Bartsch, Rupert and Bianchini, Giampaolo and Chu, Quincy and Cornelissen, Robin and Felip, Enriqueta and Girard, Nicolas and Passiglia, Francesco and Pernas, Sonia and Phillips, Melissa and Planchard, David and Zamagni, Claudio and Clark, Jo and Matthews, Cecile and Goerke, Lutz and Pistilli, Barbara},
title = {Modified Delphi Study on Oral Mucositis/Stomatitis Prevention and Management in Patients Receiving Datopotamab Deruxtecan},
journal = {European Journal of Cancer Care},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ecc/6518713}
}
EUVIMED